4.7 Article

HUME: large-scale detection of causal genetic factors of adverse drug reactions

向作者/读者索取更多资源

Motivation: Adverse drug reactions are one of the major factors that affect the wellbeing of patients and financial costs of healthcare systems. Genetic variations of patients have been shown to be a key factor in the occurrence and severity of many ADRs. However, the large number of confounding drugs and genetic biomarkers for each adverse reaction case demands a method that evaluates all potential genetic causes of ADRs simultaneously. Results: To address this challenge, we propose HUME, a multi-phase algorithm that recommends genetic factors for ADRs that are causally supported by the patient record data. HUME consists of the construction of a network from co-prevalence between significant genetic biomarkers and ADRs, a link score phase for predicting candidate relations based on the Adamic-Adar measure, and a causal refinement phase based on multiple hypothesis testing of quasi experimental designs for evaluating evidence and counter evidence of candidate relations in the patient records.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pediatrics

Cisplatin-induced nephrotoxicity in childhood cancer: comparison between two countries

Zulfan Zazuli, Catharina J. P. Op 't Hoog, Susanne J. H. Vijverberg, Rosalinde Masereeuw, Shahrad Rod Rassekh, Mara Medeiros, Rodolfo Rivas-Ruiz, Anke H. van der Zee, Bruce C. Carleton

Summary: This study evaluated the incidence of kidney injury in children who received cisplatin using different definitions. The Alt-AKI criteria detected more cases of nephrotoxicity compared to pRIFLE and KDIGO criteria. pRIFLE was more sensitive at detecting actual kidney injury and patients at risk, while KDIGO was better at detecting clinically significant kidney injury.

PEDIATRIC NEPHROLOGY (2023)

Article Pediatrics

Acute kidney injury during cisplatin therapy and associations with kidney outcomes 2 to 6 months post-cisplatin in children: a multi-centre, prospective observational study

Kelly R. McMahon, Asaf Lebel, Shahrad Rod Rassekh, Kirk R. Schultz, Tom D. Blydt-Hansen, Geoffrey D. E. Cuvelier, Cherry Mammen, Maury Pinsk, Bruce C. Carleton, Ross T. Tsuyuki, Colin J. D. Ross, Louis Huynh, Mariya Yordanova, Frederik Crepeau-Hubert, Stella Wang, Ana Palijan, Jasmine Lee, Debbie Boyko, Michael Zappitelli

Summary: This study examines the burden of acute kidney injury (AKI) and kidney outcomes in pediatric patients receiving cisplatin therapy. Severe electrolyte abnormalities were found to be associated with kidney outcomes, highlighting the need for dose optimization and follow-up guidelines in post-cisplatin care.

PEDIATRIC NEPHROLOGY (2023)

Review Health Care Sciences & Services

A Systematic Review of Polygenic Models for Predicting Drug Outcomes

Angela Siemens, Spencer J. Anderson, S. Rod Rassekh, Colin J. D. Ross, Bruce C. Carleton

Summary: Polygenic models can be used to predict complex traits and drug outcomes, but there are challenges in constructing and validating these models, such as the heterogeneity of performance measures and comparison with clinical predictors.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Article Pediatrics

Noninvasive testing for mycophenolate exposure in children with renal transplant using urinary metabolomics

Khalid Taha, Atul Sharma, Kristine Kroeker, Colin Ross, Bruce Carleton, David Wishart, Mara Medeiros, Tom D. D. Blydt-Hansen

Summary: This study aims to develop a novel urine test based on metabolomics to estimate the exposure of mycophenolate in pediatric renal transplantation. The urine samples were analyzed for 133 unique metabolites, and a top 10 urinary metabolite classifier was developed to estimate MPA exposure. The test was validated and showed correlation with allograft inflammation and eGFR ratio.

PEDIATRIC TRANSPLANTATION (2023)

Article Multidisciplinary Sciences

All-trans retinoic acid (ATRA) regulates key genes in the RARG-TOP2B pathway and reduces anthracycline-induced cardiotoxicity

Jafar S. Hasbullah, Erika N. Scott, Amit P. Bhavsar, Erandika P. Gunaretnam, Fudan Miao, Hesham Soliman, Bruce C. Carleton, Colin J. D. Ross

Summary: This study explores the effects of activating the retinoic acid pathway using all-trans retinoic acid (ATRA) on anthracycline-induced cardiotoxicity (ACT). The findings demonstrate that ATRA can reduce the toxicity of anthracyclines on human cardiomyocytes by regulating gene expression and enhancing cell survival. In a mouse model, ATRA treatment improves heart function and reduces pathological changes associated with ACT.

PLOS ONE (2022)

Article Medical Laboratory Technology

Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity

Angela Siemens, Shahrad Rod Rassekh, Colin J. D. Ross, Bruce C. Carleton

Summary: This study aimed to examine how the pharmacogenetic effects of SLC28A3, UGT1A6, and RARG are modulated by cumulative anthracycline doses in the development of cardiotoxicity. The findings suggest that the SLC28A3 variant provides more significant protection for patients receiving higher anthracycline doses, while the UGT1A6 and RARG risk variants significantly increase the risk of cardiotoxicity at low anthracycline doses.

THERAPEUTIC DRUG MONITORING (2023)

Letter Pharmacology & Pharmacy

Reply: Misidentified Dopamine Agonists Undermine Investigation Into Aripiprazole Link With Impulse Control Disorders

Mahyar Etminan, Mohit Sodhi, Bruce Carleton

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2023)

Article Biotechnology & Applied Microbiology

A luciferase reporter mouse model to optimize in vivo gene editing validated by lipid of adenine base editors

Si-Yue Yu, Tiffany Carlaw, Tyler Thomson, Alexandra Birkenshaw, Genc Basha, Daniel Kurek, Cassie Huang, Jayesh Kulkarni, Lin-Hua Zhang, Colin J. D. Ross

Summary: The development of CRISPR genome editing technology has potential for treating genetic diseases, but delivering genome editors to affected tissues is challenging. In this study, a luminescent ABE (LumA) mouse model was developed, which showed restoration of luciferase activity through A-to-G correction. The model was validated using FDA-approved lipid nanoparticle formulations and demonstrated successful restoration of luciferase activity in treated mice. This model can be used to evaluate the efficacy and safety of genome editors and delivery systems for optimizing genome editing therapeutics.

MOLECULAR THERAPY (2023)

Letter Pediatrics

Which children are still dying from asthma? A 13 year review of pediatric asthma deaths in British Columbia, Canada

Victoria E. Cook, Michael Seear, Bruce Carleton, Connie L. Yang

PEDIATRIC PULMONOLOGY (2023)

Article Medical Laboratory Technology

Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children

Angela Siemens, Beth Brooks, S. Rod Rassekh, Annelot J. M. Meijer, Mary M. van den Heuvel-Eibrink, Wei Xu, Catrina M. Loucks, Colin J. D. Ross, Bruce C. Carleton

Summary: This study found a close relationship between cisplatin dose intensity and the risk of ototoxicity in children, and this risk is further increased by the presence of TPMT-risk alleles.

THERAPEUTIC DRUG MONITORING (2023)

Review Immunology

Vaccinomics: A scoping review

Matthew Z. Dudley, Jennifer E. Gerber, Haley Budigan Ni, Madeleine Blunt, Taylor A. Holroyd, Bruce C. Carleton, Gregory A. Poland, Daniel A. Salmon

Summary: This scoping review examines the associations between human genetics and vaccine immunogenicity and safety. The study found numerous genetic determinants associated with the immunogenicity of hepatitis B, measles, rubella, and influenza vaccines. Additionally, genetic associations were reported with adverse events following influenza and measles vaccinations.

VACCINE (2023)

Article Oncology

RBL2 Regulates Cardiac Sensitivity to Anthracycline Chemotherapy

Peng Xia, Jingrui Chen, Yadav Sapkota, Erika N. Scott, Yuening Liu, Melissa M. Hudson, Shahrad R. Rassekh, Bruce C. Carleton, Colin J. D. Ross, Eric J. Chow, Zhaokang Cheng

Summary: This study found that RBL2 is an endogenous CDK2 inhibitor in the heart, which can inhibit FOXO1-mediated pro-apoptotic gene expression. Loss of RBL2 increases sensitivity to DOX-induced cardiotoxicity. These findings suggest that RBL2 could be used as a biomarker to predict the risk of cardiotoxicity before the initiation of anthracycline-based chemotherapy.

JACC: CARDIOONCOLOGY (2023)

Article Pediatrics

Urinary TIMP-2*IGFBP-7 to diagnose acute kidney injury in children receiving cisplatin

Hayton Y. Chui, Kelly R. McMahon, Shahrad Rod Rassekh, Kirk R. Schultz, Tom D. Blydt-Hansen, Cherry Mammen, Maury Pinsk, Geoffrey D. E. Cuvelier, Bruce C. Carleton, Ross T. Tsuyuki, Colin J. D. Ross, Prasad Devarajan, Louis L. Huynh, Mariya Yordanova, Frederik G. Crepeau-Hubert, Stella Wang, Vedran Cockovski, Ana Palijan, Michael Zappitelli

Summary: In this study, it was found that urine TIMP-2 and IGFBP-7 may serve as biomarkers for early detection of cisplatin-induced AKI in pediatric patients. The concentrations of these biomarkers were associated with the occurrence of AKI during cisplatin treatment.

PEDIATRIC NEPHROLOGY (2023)

Article Pediatrics

Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study

Samina Ali, Katie Gourlay, Aran Yukseloglu, Rhonda J. Rosychuk, Silvia Ortiz, Rick Watts, David W. Johnson, Bruce Carleton, Sylvie Le May, Amy L. Drendel

Summary: The study aimed to compare the frequency and intensity of adverse events in children using ibuprofen versus oxycodone for pain management following acute fractures, with oxycodone associated with more frequent and intense AEs. Additionally, lower extremity fractures were found to result in more functional limitations. Clinicians should take these differences into consideration when providing fracture pain care for children.

BMJ PAEDIATRICS OPEN (2022)

暂无数据